About 25% of lung adenocarcinomas have mutations of the gene KRAS, which drives uncontrolled cell growth. In recent years, the FDA has approved two KRAS inhibitors to treat patients with KRAS mutations. While these drugs can work well initially, tumors almost always develop resistance to them.
❓ Unknown
Lung Cancers Develop Resistance to KRAS-Inhibiting Drugs: Implications for Treatment
Just now
September 30, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
Recent research highlights that lung adenocarcinomas with KRAS mutations can develop resistance to KRAS inhibitors, which are FDA-approved treatments. This is significant as it affects global cancer treatment strategies, including in Iran where lung cancer is a health concern. Understanding these mechanisms is crucial for improving patient outcomes.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
15 min ago •
Hidden Star Cluster Garro 04 Discovered in Milky Way's Disk
15 min ago •
AI Chatbots as Language Learning Tools: Benefits and Limitations
15 min ago •
Language Patterns in Memory Tests May Indicate Early Cognitive Dysfunction
16 min ago •
Possibility of Hagel's Dismissal After the U.S. Midterm Elections
19 min ago •